联合吸入噻托溴铵及沙美特罗替卡松对稳定期COPD患者血清炎症细胞因子及肺功能的影响  

Influence of inhaled almeterol/fluticasone propionate and tiotropium bromide on plasma inflammatory cytokines and lung function in COPD patients at stable stage

作　　者：迟玉敏[1] 吕静[1] 杜俊凤[1] 姜明明[1] 邸庆国[1] 韩瑞[2] 

机构地区：[1]河北医科大学附属沧州市中心医院呼吸一科,河北沧州061000 [2]沧州市中西医结合医院东院区,河北沧州061000

出　　处：《临床肺科杂志》2013年第9期1560-1562,共3页Journal of Clinical Pulmonary Medicine

摘　　要：目的探讨联合吸入噻托溴铵及沙美特罗替卡松对稳定期重度、极重度COPD患者血浆炎症细胞因子及肺功能的影响。方法选取我院呼吸科门诊就诊的稳定期重度、极重度COPD患者80例,应用完全随机方法将患者分成两组,一组联合应用噻托溴铵及沙美特罗替卡松干粉剂(联合组),一组单用沙美特罗替卡松干粉剂(单药组),共治疗12个月。并分别于治疗前及治疗3个月、6个月、12个月测定患者血清炎症细胞因子(IL-8、TNF-α)及肺功能(FEV1、FVC、IC)。结果两组患者于治疗后各时期血清IL-8、TNF-α较治疗前均有明显下降,肺功能指标均较治疗前明显改善,差异有统计学意义(P<0.05)。结论噻托溴铵与沙美特罗替卡松联合能明显降低稳定期COPD患者IL-8、TNF-α水平,减轻气道炎症,并改善患者的肺功能。Objective To observe the influence of inhaled almeterol/fluticasone propionate and tiotropium bromide on plasma in- flammatory cytokines and lung function in COPD patients at stable to peracute stage. Methods 80 COPD patients from stable to peracute stages were randomly divided into the salmeterol/flutieasone group and the combination group. The combination group received the combi- nation therapy of tiotropium bromide and salmeterol/fluticasone propionate, and the salmeteroL/fluticasone group received salmeterol/fluti- casone propionate. The total treatment course was 12 months. The inflammatory cytokines （ IL-8, TNF-α） in blood plasma and lung func- tion （ FEV1 , IC and FVC） were determined before and after the treatment. Results The levels of IL-8 and TNF-α in blood plasma de- creased significantly, and FEV1, IC and FVC were better improved in the two groups after the treatment （ P 〈 0. 05 ）. The improvement was more pronounced in the combination group than in the salmeterol/fluticasone group. Conclusion The combination therapy of salmet- erol/fluticasone propionate and tiotropium bromide can obviously reduce the levels of inflammatory cytokines and airway inflammation and improve lung function in the treatment of COPD patients at stable stage.

关 键 词：沙美特罗替卡松 噻托溴铵 慢性阻塞性肺病 炎症细胞因子 肺功能 

分 类 号：R563.9[医药卫生—呼吸系统]